RxDoctor Payments DataLook up a doctor →

Ian Piovanetti, MD

Ophthalmology · San Juan, PRNPI 1205897154

Payments from drug & device makers

$726,099in general payments, 2019–2025

Across 1,710 payments — averaging $424.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$716K
  • Bausch & Lomb Americas Inc.$8K
  • Alcon Puerto Rico Inc$874
  • AbbVie$496
  • Novartis$305
  • NEW World Medical,inc.$188
  • plus $584 from 5 others

What the payments were for

  • Speaking & faculty fees$7,50071%
  • Food & beverage$3,05529%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$726,099 in reported general payments places this provider in the 95th percentile of 214 ophthalmology providers in Puerto Rico.

See all ophthalmology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$69,443
Medicare patients
126
Services billed
641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost472$127,933
RestasisCyclosporine142$82,101
Prednisolone Acetate849$36,043
Ketorolac Tromethamine651$18,583
Ofloxacin773$18,248
Fluorometholone272$16,975
Cyclosporine95$16,207
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol106$14,632
Alphagan PBrimonidine Tartrate70$14,145
CombiganBrimonidine Tartrate/Timolol60$13,236
XiidraLifitegrast13$9,175
Latanoprost617$8,873
Brimonidine Tartrate51$7,480
Lotemax SmLoteprednol Etabonate15$3,873
SimbrinzaBrinzolamide/Brimonidine Tart18$3,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$496$237,415744 claims
Bausch & Lomb Americas Inc.Xiidra$8,120$9,17513 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$128$3,87315 claims
AlconSimbrinza$169$3,79418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 214 ophthalmology providers in Puerto Rico.

Other ophthalmology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →